InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

Description of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

Introduction

The immune system is a complex network of cells, tissues, and organs that work together to protect the body from harmful pathogens and foreign substances. One key component of the immune system is the production of interferons, which are proteins that play a crucial role in the body’s defense against viral infections and other pathogens. In particular, interferon alpha (IFN-α) and interferon beta (IFN-β) are important in the early stages of viral infections, and their dysregulation has been linked to autoimmune diseases and cancer. The type I interferon receptor (IFNAR1) is a key therapeutic target for modulating the immune response and has been the focus of extensive research. In this article, we will discuss the structure, activity, and application of the InVivoMAb Anti-Human IFNAR1 Antibody (H3K1), a valuable tool for studying IFNAR1 and its role in immune regulation.

Structure of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

The InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is a monoclonal antibody that specifically targets the extracellular domain of the human IFNAR1 protein. It is produced by hybridoma technology, where mouse B cells are fused with myeloma cells to generate immortalized hybrid cells that produce large quantities of a single type of antibody. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, each with a variable region that recognizes IFNAR1 and a constant region that mediates effector functions.

Activity of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

The InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) has been extensively characterized for its activity in vitro and in vivo. In vitro studies have shown that the antibody specifically binds to IFNAR1 and inhibits the binding of IFN-α and IFN-β to the receptor, thereby blocking downstream signaling events. This results in the suppression of IFN-induced gene expression and biological responses, such as antiviral activity and immune cell activation. In vivo studies have demonstrated that the antibody effectively neutralizes IFNAR1 and blocks IFN signaling in animal models, leading to reduced inflammation and improved disease outcomes in various autoimmune and inflammatory disease models.

Application of InVivoMAb Anti-Human IFNAR1 Antibody (H3K1)

The InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) has multiple applications in both research and therapeutic settings. As a research tool, the antibody can be used to study the role of IFNAR1 in immune regulation and to investigate the effects of blocking IFN signaling in various disease models. It can also be used to screen for potential inhibitors of IFNAR1 and to validate the efficacy of these inhibitors in preclinical studies. In addition, the antibody can be used in diagnostic assays to detect and quantify IFNAR1 levels in patient samples.

In terms of therapeutic applications, the InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) has shown promise in the treatment of autoimmune and inflammatory diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. By blocking IFN signaling, the antibody can reduce inflammation and prevent tissue damage in these diseases. Furthermore, the antibody has potential as an adjuvant therapy in cancer treatment, as it can enhance the anti-tumor immune response by inhibiting the immunosuppressive effects of IFN signaling.

Conclusion

In summary, the InVivoMAb Anti-Human IFNAR1 Antibody (H3K1) is a valuable tool for studying IFNAR1 and its role in immune regulation.